Education
About Us
Working with TipRanks
Follow Us
DBV Technologies S.A. - American Depositary Shares (DBVT)
:DBVT
RESEARCH TOOLSreports
DBVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $12.78
Previous CloseN/A
Volume52.91K
Average Volume (3M)27.75K
Market Cap
$274.91M
Enterprise Value$121.25M
Total Cash (Recent Filing)$103.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Oct 29, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding27,389,774
10 Day Avg. Volume28,693
30 Day Avg. Volume27,753
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$14.35Price Target Upside43.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyThe Viaskin Peanut patch for toddlers showed compelling efficacy and durability in the EPITOPE trial, with a significant percentage of toddlers meeting responder criteria after 12 months.
Financial StabilityDBV secured a structured financing deal in March of up to $306.9M that is expected to support the company through commercialization in the US.
Regulatory ApprovalFDA has formalized the Accelerated Approval pathway for the Viaskin Peanut patch, which could streamline the regulatory process.
Bears Say
Clinical RiskThe VITESSE trial in peanut-allergic children (4–7 years) represents the last major clinical risk for Viaskin, with the Phase 3 trial fully enrolled and using a modified patch informed by previous studies.
Dependence On Trial SuccessSuccess in the upcoming Phase 3 VITESSE trial will satisfy requirements for the BLA submission, currently planned for H1 2026.
Market CompetitionOmalizumab biosimilars are expected to become widely available, which may reduce constraints on coverage/reimbursement of a branded agent.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies S.A. - American Depositary Shares’s price range in the past 12 months?
DBV Technologies S.A. - American Depositary Shares lowest stock price was $2.20 and its highest was $12.78 in the past 12 months.
What is DBV Technologies S.A. - American Depositary Shares’s market cap?
DBV Technologies S.A. - American Depositary Shares’s market cap is $274.91M.
When is DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date?
DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date is Oct 29, 2025 which is in 72 days.
How were DBV Technologies S.A. - American Depositary Shares’s earnings last quarter?
DBV Technologies S.A. - American Depositary Shares released its earnings results on Jul 29, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.13.
Is DBV Technologies S.A. - American Depositary Shares overvalued?
According to Wall Street analysts DBV Technologies S.A. - American Depositary Shares’s price is currently Undervalued.
Does DBV Technologies S.A. - American Depositary Shares pay dividends?
DBV Technologies S.A. - American Depositary Shares does not currently pay dividends.
What is DBV Technologies S.A. - American Depositary Shares’s EPS estimate?
DBV Technologies S.A. - American Depositary Shares’s EPS estimate is -0.32.
How many shares outstanding does DBV Technologies S.A. - American Depositary Shares have?
DBV Technologies S.A. - American Depositary Shares has 27,389,774 shares outstanding.
What happened to DBV Technologies S.A. - American Depositary Shares’s price movement after its last earnings report?
DBV Technologies S.A. - American Depositary Shares reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of DBV Technologies S.A. - American Depositary Shares?
Currently, no hedge funds are holding shares in DBVT
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.35 (43.64% Upside)
$14.35 (43.64% Upside)
Blogger Sentiment
Bearish
DBVT Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.42%
12-Months-Change
Fundamentals
Return on Equity
-148.73%
Trailing 12-Months
Asset Growth
25.61%
Trailing 12-Months
Company Description
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a biopharmaceutical company focused on developing and commercializing innovative therapies for food allergies and immunological diseases. The company is primarily engaged in the research and development of its proprietary Viaskin technology, which aims to provide a safe and effective method for desensitizing patients to allergens through epicutaneous immunotherapy. DBV Technologies operates in the biotechnology sector, with a core emphasis on addressing unmet medical needs in allergy treatment.
DBVT Stock 12 Month Forecast
Average Price Target
$14.35
▲(43.64% Upside)
Technical Analysis
Protalix
―
Cidara Therapeutics
―
Corvus Pharmaceuticals
―
enGene Holdings
―
CARGO Therapeutics, Inc.
―
Ownership Overview
0.81% Insiders
0.02% Mutual Funds
10.88% Other Institutional Investors
88.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---